arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CORCEPT THERAPEUTICS INC

CORT
$110.77 ▲ +2.88 (+2.66%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Bullish
auto_awesome

Analytical Summary

CORCEPT THERAPEUTICS INC shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $11.5B
Dividend Yield
Revenue Growth 12.8%
Op. Margin 5.9%
ROIC 10.4%
FCF / Share $1.37
Trailing P/E 116.6x
Price / Book 18.1x
FCF Yield 1.2%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$761.41M
↑ +12.8%
Net Income Profit after all expenses
$99.65M
↓ -29.4%
Operating Margin Operating profit as % of sales
5.9%
↓ -71.0% 45th
FCF / Share Free cash flow per share
$1.37
↓ -28.1%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
65
Returns
81
Cash Quality
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 27 years · 77 quarters